Last updated on November 2018

Phase 1/2 Study Exploring the Safety Tolerability and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Brief description of study

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

Clinical Study Identifier: NCT03126110

Contact Investigators or Research Sites near you

Start Over

Dr. Frederic Forget

CHA Centre Hospitalier de l'Ardenne
Libramont, Belgium
  Connect »